HHC

# Research Output: HHC (Hexahydrocannabinol)

**PSX ID:** PSX-0407  
**Research date:** 2026-05-07  
**Provenance ID:** 544bcc9f-d777-412d-a3bb-1bc8547e5ee0

---

## Chemical Identity

**Verified against PubChem CID 16050328** (9R-epimer; the (9S)-epimer has a separate CID). The brief seed data contained no chemical fields — all values below are research-derived and should be pushed to the database.

| Field | Verified Value | Source |
|---|---|---|
| Molecular formula | C₂₁H₃₂O₂ | PubChem CID 16050328 |
| Molecular weight | 316.5 g/mol | PubChem CID 16050328 |
| IUPAC name | (6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-1-ol | PubChem CID 16050328 |
| InChIKey | XKRHRBJLCLXSGE-VNCLPFQGSA-N | PubChem CID 16050328 |
| PubChem CID | 16050328 (9R); a distinct CID exists for (9S) | PubChem |
| Systematic name | (9R)-Hexahydrocannabinol / (6aR,9R,10aR)-HHC (active epimer) | Multiple sources |

**Stereochemistry note:** HHC exists as two diastereomers that are not interconverted under normal conditions. The C9 chiral center determines psychoactivity:
- **(9R)-HHC** (also called 11β-HHC or "beta-HHC"): the pharmacologically active epimer; comparable activity to Δ⁹-THC at CB1. EC₅₀ = 53.4 nM at CB1 (Haghdoost et al. 2024 [Ref 38]).
- **(9S)-HHC** (also called 11α-HHC or "alpha-HHC"): the weakly active epimer. EC₅₀ = 624.3 nM at CB1, approximately 12× less potent than the (9R) form (Haghdoost et al. 2024 [Ref 38]).

Commercial products contain both epimers in variable ratios. Examination of >60 commercial HHC products found (9R):(9S) ratios ranging from 0.2:1 to 2.4:1 (Nasrallah & Garg 2023 [Ref 39]). Catalytic hydrogenation of Δ⁹-THC using Adams' catalyst affords approximately 1:7 (9S):(9R) ratio; i.e., (9R)-HHC is the major product (PMC10490552 [Ref 24]).

**Natural occurrence:** HHC occurs in trace quantities in cannabis pollen and seeds. Casati et al. (2024 [Ref 37]) were among the first to document and quantify both epimers in commercialized hemp-derived products (42.5% (9R)-HHC and 23.6% (9S)-HHC by weight in resin samples, with remaining content composed of other cannabinoids and carrier substances). The DEA has disputed natural-origin classification, stating in a 2023 letter that HHC "does not occur naturally in the cannabis plant and can only be obtained synthetically" — this characterization is contested by published phytochemical literature [Ref 32].

**Physical properties:** No published melting point, aqueous solubility, or stability data specifically for HHC epimers was found in the peer-reviewed literature. The compound is lipophilic (consistent with the cannabinoid scaffold; logP not formally determined for HHC in the literature reviewed).

---

## Pharmacology

### Receptor binding and mechanism

HHC is a partial agonist of the cannabinoid CB1 receptor [Refs 38, 39]. Both epimers have been characterized:

- **(9R)-HHC:** CB1 partial agonist, EC₅₀ = 53.4 nM; comparable binding pose to Δ⁹-THC inside the receptor pocket (Haghdoost et al. 2024 [Ref 38]). Binding affinity and functional activity described as "similar to Δ⁹-THC" (Nasrallah & Garg 2023 [Ref 39]).
- **(9S)-HHC:** CB1 partial agonist, EC₅₀ = 624.3 nM; adopts a different binding posture within the CB1 receptor that explains its weak agonist activity. Despite strong binding affinity in some assays, (9S)-HHC shows markedly diminished functional activity (Haghdoost et al. 2024 [Ref 38]; Nasrallah & Garg 2023 [Ref 39]).
- **Stereospecificity mechanism:** Reggio et al. (1989 [Ref 4]) demonstrated via molecular mechanics that the (9R) (11β) configuration produces a chair conformation of the carbocyclic ring that orients the C9 substituent in a manner critical for activity, while the (9S) (11α) configuration allows chair or twist conformations with different C9 orientation.

In a β-arrestin2 CB1 recruitment bioassay (Janssens et al. 2024 [Ref 16]), HHC and its propyl homolog HHCP were identified as having higher CB1 activation potential than Δ⁹-THC based on either higher Emax or higher potency (EC₅₀). The relative abundance of the less active (9S) epimer in seized products reduced apparent potency but sustained overall efficacy for the mixture. The WHO ECDD (2024 [Ref 23]) concluded that HHC has higher affinity and agonist activity at CB1 compared to CB2, consistent with sedative, analgesic, mood-altering, and anxiogenic effects.

**FLAG for editorial review:** No Ki values at CB1 or CB2 via radioligand displacement specifically for unmodified HHC are available in the literature reviewed. The Haghdoost EC₅₀ values are from a functional CB1 agonism assay (cAMP or equivalent), not a binding displacement assay. The Nasrallah & Garg binding data are described qualitatively ("similar to Δ⁹-THC") without a published Ki number. A specific CB2 EC₅₀ for HHC was not found.

### Animal pharmacology

**Rat (Šíchová et al. 2025 [Ref 17]):** A 1:1 mixture of (9R)- and (9S)-HHC administered intragastrically to male Wistar rats at 1, 5, and 10 mg/kg. Key findings:
- Peak blood and brain concentrations observed 2 hours post-administration at 10 mg/kg
- HHC readily crosses the blood-brain barrier
- At 10 mg/kg (highest dose): reduced locomotor activity, increased anxiety (open field test), impaired sensorimotor gating (prepulse inhibition of acoustic startle response)
- OECD 423 acute oral toxicity: **classified Category 4, estimated LD₅₀ ≈ 1000 mg/kg** (species: rat, male Wistar)
- Overall profile described as "similar to tetrahydrocannabinol"
- Dose-dependent anxiogenic properties noted

**Historical context:** Preclinical studies from the cannabinoid scaffold research era (pre-2020) consistently found that HHC analogs with the β (9R) configuration produce THC-like effects in mouse tetrad assays (catalepsy, hypoactivity, hypothermia, antinociception), while α (9S) analogs are minimally active (Reggio et al. 1989 [Ref 4]).

### Pharmacokinetics (Human)

Two controlled self-administration studies provide the primary human PK data:

**Höfert et al. (2025 [Ref 6]):** 25 mg HHC (fruit gum, oral) vs. inhalation (3 puffs vape), n=3 per group. Serum, urine, and saliva sampled up to 48h (serum), 5 days (urine). Key findings:
- Overall PK profile comparable to THC
- Route of administration and inter-individual factors were critical determinants
- Subjective "high" scale 0–10 was monitored; psychophysical tests (modified Romberg, walk-and-turn) documented impairment

**Lucuta et al. (2025 [Ref 7]):** Plasma concentrations after oral 25 mg HHC vs. inhalation (95% HHC vape). Key concentration data:
- **Inhalation:** Peak (9R)-HHC ≈ 65 ng/mL and (9S)-HHC ≈ 21 ng/mL at approximately 5 minutes (~0.08h) post-inhalation
- **Oral:** Peak (9R)-HHC ≈ 3.8 ng/mL and (9S)-HHC ≈ 2.5 ng/mL at approximately 1.16h post-ingestion
- **Metabolites (oral):** (9R)-OH-HHC 0.3–1.4 ng/mL; (9R)-COOH-HHC 0.8–17 ng/mL
- Cannabimimetic effects after oral: slight vertigo, slight headache, dizziness, dry mouth
- After inhalation: one participant showed distinct cannabimimetic impairments

**Forensic cases (Grapp et al. 2025 [Ref 12]):** In 599 serum samples from forensic cases (suspected cannabis use), 25 samples were HHC-positive. Serum concentrations: (9R)-HHC 0.15–14.4 ng/mL; (9S)-HHC 0.14–5.76 ng/mL.

### Metabolism

Metabolism is similar to Δ⁹-THC (Pitterl et al. 2024 [Ref 8]; Lindbom et al. 2025 [Ref 9]):

**Phase I reactions:**
- Primary: monohydroxylation → 11-OH-HHC (major), 5'-OH-HHC (major), 8(R)OH-9(R)-HHC (major urinary metabolite)
- Secondary: oxidation to carboxylic acids → (9R)- and (9S)-HHC-COOH (11-nor-9-carboxy-HHC)
- CYP enzyme involvement: similar to THC (CYP2C9, CYP3A4 inferred by class; no HHC-specific CYP mapping studies found)

**Phase II:** Extensive glucuronidation — 99.3% of hydroxylated metabolites are glucuronidated (Lindbom et al. 2025 [Ref 9])

**Detection note:** HHC parent compound is detectable in plasma but not typically in urine (Pitterl et al. 2024 [Ref 8]). Urinary biomarkers are hydroxylated metabolites (glucuronide-conjugated); 11-OH-HHC, 5'-OH-HHC, and 8(R)OH-9(R)-HHC found in all urine samples across studies.

**Diagnostic complication:** (9R)-HHC-COOH has been identified as a minor metabolite of Δ⁹-THC itself; (9S)-HHC-COOH is the predominant isomer in urine from THC-only users. A serum cutoff of ≥30% (9R)-HHC-COOH/THC-COOH ratio has been proposed to distinguish HHC consumption from THC-alone use (Grapp et al. 2025 [Ref 12]).

**Immunoassay cross-reactivity:** HHC, HHC-COOH, and related metabolites cross-react with standard THC immunoassays, causing false-positive THC screening results. In Sweden, after HHC appeared in 2022, false-positive THC oral fluid screens rose from <2% to >10% (Helander et al. 2024 [Ref 10]).

**HHC acetate (HHC-O):** The acetate ester (HHC-O) is rapidly de-esterified to HHC in vivo, so the active species is HHC itself (Lindbom et al. 2025 [Ref 9]).

---

## History

**Discovery and early synthesis (1940s):**
HHC was first synthesized and described pharmacologically by Roger Adams in 1940. Adams and collaborators published in the *Journal of the American Chemical Society* during 1940–1941, investigating tetrahydrocannabinol homologs and analogs in the context of identifying the psychoactive principles of marijuana and hashish. Key historical work: Adams R, Smith CM, Loewe S, "Tetrahydrocannabinol homologs and analogs with marihuana activity XI" (JACS 1941). The patent US2419937A, describing synthesis of hexahydrocannabinol among other "marihuana active compounds," was filed March 27, 1944, and granted May 6, 1947, to Roger Adams [Ref 22]. Throughout the 1940s–1980s, HHC was studied primarily as a pharmacological tool for understanding cannabinoid SAR. 11β-HHC (the 9R epimer) was identified early as the active form, while 11α-HHC (9S) was recognized as minimally active — a distinction confirmed by Reggio et al. (1989 [Ref 4]).

**Modern pharmaceutical research (1990s–2010s):**
HHC served as a scaffold for medicinal chemistry, particularly in the Makriyannis and Nikas groups. Novel C-ring-hydroxy-substituted HHC analogs (e.g., AM7499) were developed as controlled-deactivation cannabinergic ligands (Kulkarni et al. 2016 [Ref — see OpenAlex W2472242733]).

**Market emergence (2021–present):**
HHC appeared on the US recreational drug market in approximately September 2021, following the 2018 Farm Bill which legalized hemp-derived CBD — providing a cheap, legal precursor for semi-synthetic cannabinoid manufacture. The synthesis route currently used commercially involves: (1) acid-catalyzed cyclization of CBD to a Δ⁸/Δ⁹-THC mixture, followed by (2) catalytic hydrogenation to produce a mixture of (9R)- and (9S)-HHC epimers (Ujváry 2024 [Ref 1]). HHC first appeared in Europe in May 2022. By 2023, it was the predominant semi-synthetic cannabinoid in multiple European markets. As of 2022, 36 countries and territories had reported HHC to UNODC (WHO ECDD 47th report [Ref 23]).

**International scheduling:**
The WHO ECDD 47th meeting (October 14–18, 2024) critically reviewed HHC and recommended placement in Schedule II of the 1971 Convention on Psychotropic Substances [Ref 23]. The UN Commission on Narcotic Drugs (CND), 68th session, voted to implement this in March 2025.

---

## Subjective Effects

**Published descriptions from controlled human studies:**

From Höfert et al. (2025 [Ref 6]) (most rigorous human study to date):
- Subjective "high" feeling was documented (scale 0–10), with effects noted to be comparable to THC
- Route of administration heavily influenced intensity and duration
- Psychophysical impairments documented (modified Romberg test, walk-and-turn)

From Lucuta et al. (2025 [Ref 7]):
- Oral (25 mg): slight vertigo, slight headache, dizziness, dry mouth / dehydration sensation
- Inhalation: one participant showed distinct cannabimimetic impairments suggesting inhalation produces more pronounced acute effects

From Šíchová et al. (2025 [Ref 17], rat model):
- Reduced locomotor activity (sedation)
- Increased anxiety (anxiogenic at high doses)
- Impaired sensory processing / sensorimotor gating

**User reports and market context (from reviews):**
Caprari et al. (2024 [Ref 25]) and Ujváry (2024 [Ref 1]) describe user-reported effects from online forums as similar to Δ⁹-THC: euphoria, relaxation, altered perception of time, appetite enhancement, sedation. Potency described by users as somewhat less than Δ⁹-THC, though product variability in epimer ratios makes this unreliable (Nasrallah & Garg 2023 [Ref 39]).

**Effects taxonomy mapping (based on CB1 agonism and available evidence):**
The following effects are documented or strongly inferred from published data:
- *Body:* sedation, body high, dry mouth, dizziness, appetite enhancement, motor control impairment, nausea (at higher doses)
- *Thinking:* cognitive impairment, memory suppression, focus suppression
- *Feeling:* euphoria, anxiety (dose-dependent, especially at high doses), paranoia (reported)
- *Perception:* visual effects comparable to cannabis (not separately characterized for HHC)
- *Self:* disinhibition, time alteration (inferred from CB1 agonism and user reports)

**⚠ FLAG:** No published controlled human study with dose-ranging, subjective effect scales (ARCI, DEQ, VAS), or full effect characterization has been published as of the research cutoff date. The Höfert and Lucuta studies are pilot pharmacokinetic studies with n=3 per group; not powered for effect quantification. All effects mapping beyond what is directly documented should be clearly labeled as inferred from CB1 pharmacology or user reports.

---

## Safety & Toxicity

### Acute toxicity

**Rat, oral (Šíchová et al. 2025 [Ref 17]):**
- OECD 423 classification: **Category 4** substance
- Estimated LD₅₀ ≈ **1000 mg/kg** (oral, male Wistar rat)
- This places HHC in the same toxicity category as Δ⁹-THC (which also has a very low acute oral toxicity profile)

**FLAG:** No LD₅₀ data in other species. No published human overdose series specifically for HHC. LD₅₀ value is based on a single animal study. Flag as requiring verification.

### Case reports

The following adverse events are documented in the published literature:

**HHC-analogue intoxications (not pure HHC, but directly relevant):**
- Thomsen et al. (2025 [Ref 18]): Two patients hospitalized after HHC-C8 (octyl homolog) intoxication. Case 1: young male, deep unconsciousness, recurring seizures, **coma for 2 days**, gradual recovery over 2 weeks; HHC-C8 blood concentration 72 ng/mL at admission. Case 2: female, prolonged sedation, minimally responsive for 3 days. Product contained 6–7% HHC-C8.
- Reiter et al. (2025 [Ref 19]): Male in early 40s admitted after ingestion of 40 mg HHC-C9 (nonanyl homolog); vomiting, visual disturbances, **9 days of cognitive and physical impairment**. HHC-C9 confirmed in blood by forensic toxicology.

**Note:** These case reports are for homologs with longer alkyl side chains (C8, C9 vs. HHC's C5 pentyl side chain). Longer-chain homologs are generally more potent at CB1. These cases should not be directly extrapolated to typical HHC (pentyl-chain), but they illustrate the spectrum of potential harm from products in the same chemical family.

**HHC (pentyl) adverse events:**
- Controlled human study data (Lucuta et al. 2025 [Ref 7]): after inhalation of 95% HHC vape, one of three participants showed "distinct impairments." This is too small a sample to characterize adverse risk.
- Höfert et al. (2025 [Ref 6]): adverse effects not specifically quantified beyond psychomotor impairment in pilot cohort.
- Ireland survey data (Mongan et al. 2025 [Ref 21]): HHC sold openly in Ireland until July 2025; reports of **psychotic illness precipitated by HHC use** documented. No case series published at time of research.

**Product safety concerns:**
- Commercial HHC products contain widely variable (9R):(9S) ratios (0.2:1 to 2.4:1), meaning potency is inconsistent batch-to-batch (Nasrallah & Garg 2023 [Ref 39])
- Semi-synthetic production routes may introduce byproducts including unreacted Δ⁸/Δ⁹-THC, reaction intermediates, and catalyst residues (Zawatsky et al. 2024 [Ref 26])
- HHC-O (acetate) is often co-present in "HHC products" and is rapidly de-esterified to HHC in vivo

### Psychological risks

By class inference from CB1 agonism pharmacology and analogy with Δ⁹-THC:
- Anxiety and paranoia (documented as dose-dependent in rat study; reported by users)
- Psychosis risk (documented from Ireland reports [Ref 21]; biologically plausible given CB1 agonism)
- Cognitive impairment during acute intoxication (documented in human controlled studies)

---

## Harm Reduction

### Routes of administration and risk profile

**Inhalation (vaping, smoking):** Fastest onset (<1 min), highest peak plasma concentrations (~65 ng/mL for (9R)-HHC), most unpredictable dosing due to product variability. Greater acute impairment documented. Vaping products introduce additional respiratory exposure risks (solvent residues, vitamin E acetate as potential cutting agent — by analogy with EVALI risk documented for Δ⁸-THC vapes; Zawatsky et al. 2024 [Ref 26]).

**Oral (edibles/gummies):** Slower onset (~1–2h), lower peak plasma (~3.8 ng/mL), more prolonged effects. Risk of redosing before effects peak.

**Dose uncertainty:** No established human therapeutic or recreational dose range. The (9R):(9S) ratio variability means a given milligram dose will have different effective (9R)-HHC content. This is a critical harm reduction gap.

### Drug testing implications

HHC metabolites cross-react with immunoassay THC screens (Helander et al. 2024 [Ref 10]; Pettersson-Pablo & Oxelbark 2024 [Ref 13]; Tsujikawa et al. 2025 [Ref 14]). Users should be aware:
- Standard urine immunoassay tests (CLIA EMIT, etc.) will likely test positive for cannabinoids after HHC use
- Confirmatory GC-MS/LC-MS tests typically used to confirm THC-COOH may return negative for Δ⁹-THC-COOH but positive for HHC-COOH — which may be reported as a "false positive" by laboratories not testing for HHC metabolites specifically
- DrugScreen® urine panel cross-reacted with HHC metabolites (25 ng/mL THC-COOH cutoff); DrugWipe® oral fluid (5S) did NOT cross-react (Lucuta et al. 2025 [Ref 7])

### Recommended harm reduction practices

**(Based on published literature, not proprietary recommendations)**
1. Do not use if operating vehicles or machinery — motor control impairment documented (Höfert et al. 2025 [Ref 6]; Lucuta et al. 2025 [Ref 7])
2. Start with very low doses given product potency variability and lack of dose-response data
3. Avoid if predisposed to anxiety, psychosis, or cannabis use disorder
4. Do not combine with CNS depressants (alcohol, opioids, benzodiazepines) — additive CNS depression expected by class
5. Verify product epimer composition if possible — wide (9R):(9S) variability affects potency

---

## Tolerance & Dependence

### Tolerance

No HHC-specific tolerance studies in humans or animals have been published as of the research cutoff date.

By class inference: Cannabinoids acting at CB1 produce tolerance via CB1 receptor downregulation and desensitization with repeated use. Cross-tolerance with Δ⁹-THC is expected and biologically plausible given shared CB1 mechanism. The magnitude and time course of tolerance for HHC specifically has not been studied.

**FLAG:** All tolerance statements are class-inference only. No substance-specific data.

### Dependence

No HHC-specific dependence studies. No published reports of HHC withdrawal syndrome.

By class inference from CB1 agonism: Cannabinoid use disorder is established for Δ⁹-THC. Regular HHC use would be expected to produce similar (if somewhat different intensity) dependence liability. The partial agonist nature of HHC at CB1 (both epimers) may reduce — but does not eliminate — dependence liability compared to full agonists.

**FLAG:** All dependence statements are class-inference only. The Ireland survey (Mongan et al. 2025 [Ref 21]) documented use patterns but no published quantitative dependence data for HHC.

---

## Interactions

### Class-based interaction risk (no HHC-specific data available)

**⚠ FLAG:** No published drug interaction studies specifically for HHC have been identified. The following is inferred from the cannabinoid class and shared metabolic pathways:

**CYP enzyme interactions:**
- Other cannabinoids (THC, CBD) inhibit CYP2C9, CYP2C19, and CYP3A4 (Doohan et al. 2021 [Ref 29]; Bansal et al. 2023 [Ref 30]). HHC is metabolized via similar CYP-mediated pathways (CYP2C9, CYP3A4 inferred) and may inhibit these enzymes at therapeutic concentrations
- Clinically relevant interactions predicted with: warfarin (CYP2C9 substrate), clopidogrel, NSAIDs, antiepileptics metabolized by CYP2C9/3A4

**CNS interactions (additive/synergistic):**
- Alcohol, opioids, benzodiazepines, sedatives: additive CNS depression, sedation, respiratory depression
- Other cannabinoids (especially from uncharacterized product contents): pharmacodynamic summation
- Anticholinergics: additive (dry mouth, tachycardia, cognitive impairment)

**Monoamine interactions:**
- MAOIs: no specific data; by class caution applies with CNS-active compounds

---

## Legal Status

### United States
- **Federal:** Schedule I Controlled Substance, drug code **7220** (DEA final rule, Federal Register, May 4, 2026) [Ref 32]
- DEA position (stated in Feb 2023 Terrence Boos letter): HHC "does not occur naturally in the cannabis plant and can only be obtained synthetically, therefore does not fall under the definition of hemp"
- Prior to May 4, 2026, HHC was implicitly controlled under the existing Schedule I THC category (drug code 7370); the 2026 rule gives it a specific code (7220)
- **State-level status:** Varied; some states had explicitly banned HHC before federal action; others had not

### United Kingdom
- **Status:** Illegal. HHC is not specifically scheduled under the Misuse of Drugs Act 1971, but is covered by the **Psychoactive Substances Act 2016**, making it illegal to produce, supply, or import for human consumption

### European Union
Key dates and country-level bans:
| Country | Status | Date |
|---|---|---|
| France | Banned | 2023 (among first EU countries) |
| Germany | Added to Narcotics Act | 2023 |
| Austria | Added to controlled substances | 2023 |
| Poland | Controlled | April 14, 2023 |
| Sweden | Classified as narcotic | **July 11, 2023** (HHC and HHCP scheduled simultaneously) |
| Ireland | Controlled | July 2025 [Ref 21] |

### International
- **UN CND 68th session (March 2025):** Voted to place HHC in **Schedule II of the 1971 Convention on Psychotropic Substances** (equivalent to controlled/psychoactive substance schedule). This decision followed the WHO ECDD 47th meeting recommendation (October 2024) [Ref 23]
- 36 countries and territories had reported HHC to UNODC as of the WHO ECDD critical review (2024)

### Canada, Australia
- No specific scheduling information confirmed in sources reviewed. **FLAG for editorial review and legal verification.**

---

## Clinical Trials

No clinical trials for HHC have been identified on ClinicalTrials.gov (search performed May 7, 2026, zero results). No registered trials in any jurisdiction found. This is expected for an emerging substance that was only recently controlled internationally.

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief.

---

## Gaps & Flags

### Critical gaps requiring editorial attention

1. **⚠ SAFETY-CRITICAL — Dose range (human):** No published human dose-response study for HHC exists. The only human data is from two pilot studies with n=3 per group (Höfert et al. 2025 [Ref 6]; Lucuta et al. 2025 [Ref 7]) using a fixed oral dose (25 mg) and inhalation. No threshold, common recreational dose, or heavy dose has been established in published literature. Any dose table in the article must be based on class inference + community consensus and clearly labeled as such with a safety-critical flag.

2. **⚠ SAFETY-CRITICAL — Effect duration:** No published data on total effect duration for HHC. PK data (Höfert et al. 2025) shows serum detection for up to 48h, but subjective duration is not reported with adequate precision. Duration must be estimated from THC analogy.

3. **Binding affinity (Ki):** No published Ki value at CB1 or CB2 via radioligand displacement assay for unmodified HHC. Available data are EC₅₀ values from functional (β-arrestin or cAMP) assays. The article should note this distinction.

4. **CB2 activity:** No EC₅₀ or Ki for HHC at CB2 was identified in published literature. Class inference predicts lower CB2 vs CB1 affinity, consistent with WHO ECDD characterization.

5. **CYP enzyme mapping:** No published in vitro CYP metabolism/inhibition study specifically for HHC. All CYP interaction data is by class inference from Δ⁹-THC and CBD studies.

6. **Tolerance and dependence:** No HHC-specific data. All statements must be labeled as class-inference from CB1 agonism pharmacology.

7. **Withdrawal:** No characterization of HHC withdrawal in humans or animals.

8. **LD₅₀ species note:** Only one LD₅₀ study (rat, oral); extrapolation to humans cannot be made directly.

9. **Natural vs. synthetic origin:** There is a published dispute between the DEA's 2023 statement (claiming HHC is purely synthetic) and published phytochemical literature documenting trace HHC in cannabis pollen and seeds (Casati et al. 2024 [Ref 37]). The generation agent should present both positions.

10. **Canada/Australia legal status:** Not confirmed in sources reviewed — flag for legal editorial verification.

11. **HHC-O (acetate) distinction:** HHC-O is a separate compound (acetate prodrug of HHC) that appears in some commercial products. It is rapidly hydrolyzed to HHC in vivo. The article should briefly note this but should not conflate HHC-O adverse events with HHC.

12. **HHC-C8/C9 case reports:** The two serious case reports identified (coma, prolonged cognitive impairment) are for HHC-C8 and HHC-C9, which are higher-alkyl-chain homologs significantly more potent than HHC. These should not be presented as HHC adverse events without clear qualification.

### Data quality notes
- The most recent and relevant pharmacokinetic human data (Höfert et al. 2025; Lucuta et al. 2025) are small n=3 pilot studies; findings should be characterized as preliminary
- The Šíchová et al. 2025 rat toxicology study is the only published animal pharmacokinetics/toxicology study specifically for HHC; findings are from a single study
- No independent human pharmacological characterization study (dose-ranging, effect scales, abuse potential) has been published as of May 2026